Priority 2 from the Kidney Transplant PSP
|Extra information provided by this PSP
|Original uncertainty examples
How should decisions regarding personalisation of immunosuppression to maximize graft and recipient survival be informed? Post transplant: Possible complications? Additional procedures required? i.e. stent removal, dialysis access removal etc? Reasons why different immunosuppressants are selected for different patients? Would it be possible to have individualized protocols post transplant rather then one rule for all? how can we determine how much immunosuppression is right There are more young patients surviving. They have to face multiple transplants, dialysis and taking anti rejection medication for very long periods of time. How can we protect these patients from the long term use of these drugs? What is the most effective immunosuppression for children post transplantation? Which immunosuppressive regimen provides the best survival and quality of life in elderly transplant recipients?
|Patients x 3, Clinicians x 4
|Outcomes to be measured
|Patient and graft survival, graft function, adverse events
|PSP unique ID
|Total number of uncertainties identified by this PSP.
|90 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
|Date of priority setting workshop
|3 February 2016